MX2017008730A - Composicion que contiene establemente una molecula de acido nucleico. - Google Patents

Composicion que contiene establemente una molecula de acido nucleico.

Info

Publication number
MX2017008730A
MX2017008730A MX2017008730A MX2017008730A MX2017008730A MX 2017008730 A MX2017008730 A MX 2017008730A MX 2017008730 A MX2017008730 A MX 2017008730A MX 2017008730 A MX2017008730 A MX 2017008730A MX 2017008730 A MX2017008730 A MX 2017008730A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid molecule
composition
composition containing
containing nucleic
Prior art date
Application number
MX2017008730A
Other languages
English (en)
Inventor
Toyofuku Hidekazu
Yamada Taimu
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Publication of MX2017008730A publication Critical patent/MX2017008730A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una composición que contiene una molécula de ácido nucleico y una solución reguladora, y que tiene las características de (a) estar en la forma de una solución a temperatura ambiente; y (b) un contenido de la molécula de ácido nucleico después de almacenarse a 25°C, a 60% de humedad relativa por 4 semanas, de no menos de 80% en relación con el contenido al momento de iniciar el almacenamiento.
MX2017008730A 2014-12-29 2015-10-30 Composicion que contiene establemente una molecula de acido nucleico. MX2017008730A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014267087 2014-12-29
JP2015081298 2015-04-10
PCT/JP2015/080849 WO2016108264A1 (ja) 2014-12-29 2015-10-30 核酸分子を安定に含有する組成物

Publications (1)

Publication Number Publication Date
MX2017008730A true MX2017008730A (es) 2017-11-17

Family

ID=56284418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008730A MX2017008730A (es) 2014-12-29 2015-10-30 Composicion que contiene establemente una molecula de acido nucleico.

Country Status (14)

Country Link
US (2) US20180036409A1 (es)
EP (1) EP3241903A4 (es)
JP (2) JP6462723B2 (es)
KR (2) KR20220035404A (es)
CN (1) CN107208094A (es)
AU (2) AU2015373071B2 (es)
BR (1) BR112017014090A2 (es)
CA (1) CA2971830A1 (es)
HK (1) HK1244030A1 (es)
IL (1) IL252905B (es)
MX (1) MX2017008730A (es)
RU (1) RU2723032C2 (es)
SG (1) SG11201705312PA (es)
WO (1) WO2016108264A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016346703B2 (en) 2015-10-30 2020-07-02 Hirofumi Takeuchi Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene
FR3058061A1 (fr) * 2016-10-27 2018-05-04 Selexel Nouvelle utilisation d'oligonucleotides double brin
US20210292755A1 (en) * 2016-10-27 2021-09-23 Selexel Novel double-stranded oligonucleotides for the treatment of cancer
CN106857502A (zh) * 2017-03-03 2017-06-20 湖北新纵科病毒疾病工程技术有限公司 一种防止rna降解的样品保存液以及保存方法
US11326163B2 (en) 2017-07-28 2022-05-10 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
US20210188895A1 (en) 2017-10-13 2021-06-24 Bonac Corporation Single-stranded nucleic acid molecule, and production method therefor
EP3765476A2 (en) * 2018-03-13 2021-01-20 Janssen Pharmaceutica NV Modified oligonucleotides for use in treatment of tauopathies
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58102724A (ja) 1981-12-15 1983-06-18 Mitsubishi Chem Ind Ltd 防滑性ポリプロピレン成形品
JP2708960B2 (ja) 1990-08-16 1998-02-04 アイシス・ファーマシューティカルス・インコーポレーテッド サイトメガウイルス感染の作用を変調するオリゴヌクレオチド
DE69732029T2 (de) * 1996-04-26 2006-02-23 Merck & Co., Inc. Dna enthaltende impfstoffen
AU733674B2 (en) 1996-10-25 2001-05-24 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
ZA99493B (en) * 1998-01-30 1999-07-22 Akzo Nobel Nv Method for the isolation of nucleic acid.
CA2322232A1 (en) * 1998-03-13 1999-09-16 American Home Products Corporation Lyophilized polynucleotide composition, method of preparation, and uses thereof
DE19836559A1 (de) * 1998-08-12 2000-03-23 Antigen Gmbh Gefäß zur Entnahme von Blut
AU769771B2 (en) * 1999-12-02 2004-02-05 Hymo Corporation Polyacrylamide precast gels for electrophoresis, process for producing the same and electrophoresis method by using the gels
JP3967516B2 (ja) * 2000-02-29 2007-08-29 ハイモ株式会社 Ｄｎａの電気泳動法
DE10006662A1 (de) * 2000-02-15 2001-08-23 Antigen Produktions Gmbh Gefäß zur Nukleinsäureanalytik
US20040058886A1 (en) * 2002-08-08 2004-03-25 Dharmacon, Inc. Short interfering RNAs having a hairpin structure containing a non-nucleotide loop
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
BRPI0411505A (pt) * 2003-06-18 2006-07-25 Yissum Res Dev Co uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
EA009447B1 (ru) * 2003-09-17 2007-12-28 Сентельон Способ получения плазмидной днк фармацевтического качества
BRPI0515553A (pt) * 2004-09-17 2008-07-29 Centelion formulações lìquidas estáveis de dna de plasmìdeo
DE102005023170A1 (de) * 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
TW201336514A (zh) * 2006-04-13 2013-09-16 Alcon Res Ltd ＲＮＡ干擾（ＲＮＡｉ）所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用（二）
CA2709875C (en) * 2008-01-02 2019-07-16 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
JP5608998B2 (ja) * 2009-03-31 2014-10-22 東洋紡株式会社 保存安定性に優れた核酸増幅検出試薬キット
US8691782B2 (en) * 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
DK3202760T3 (da) * 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc Pegylerede lipider og deres anvendelse til lægemiddelfremføring
JP6133883B2 (ja) * 2011-11-04 2017-05-24 日東電工株式会社 薬物送達用の脂質ナノ粒子の生成方法
GEP201606581B (en) * 2012-03-15 2016-11-25 Acraf Glycogen-based cationic polymers
EP2846839B1 (en) * 2012-05-10 2019-02-20 Adynxx, Inc. Formulations for the delivery of active ingredients
WO2014134797A1 (zh) * 2013-03-06 2014-09-12 百奥迈科生物技术有限公司 脂质体制剂、制备方法及其应用

Also Published As

Publication number Publication date
IL252905B (en) 2020-09-30
JP2019077696A (ja) 2019-05-23
IL252905A0 (en) 2017-08-31
HK1244030A1 (zh) 2018-07-27
WO2016108264A1 (ja) 2016-07-07
JPWO2016108264A1 (ja) 2017-08-31
KR102585112B1 (ko) 2023-10-10
JP6462723B2 (ja) 2019-01-30
AU2022204391A1 (en) 2022-07-14
RU2017126568A3 (es) 2019-05-20
AU2015373071B2 (en) 2022-03-31
KR20170094797A (ko) 2017-08-21
CN107208094A (zh) 2017-09-26
US20240016937A1 (en) 2024-01-18
RU2723032C2 (ru) 2020-06-08
JP6808710B2 (ja) 2021-01-06
US20180036409A1 (en) 2018-02-08
CA2971830A1 (en) 2016-07-07
EP3241903A4 (en) 2018-07-04
RU2017126568A (ru) 2019-01-31
KR20220035404A (ko) 2022-03-22
BR112017014090A2 (pt) 2018-03-06
EP3241903A1 (en) 2017-11-08
AU2015373071A1 (en) 2017-07-13
SG11201705312PA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
MX2017008730A (es) Composicion que contiene establemente una molecula de acido nucleico.
MX2017013878A (es) Amplificación de discordancias optimizadas multiplicadas (moma) - reacción en cadena de polimerasa (pcr) en tiempo real, para evaluar el ácido desoxirribonucleico (adn) libre de celula.
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
MX2019005199A (es) Métodos para evaluar el riesgo usando and libre de células total y específico.
EA201890926A1 (ru) ТРИАЗОЛОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
EA201892123A1 (ru) 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
ZA202001294B (en) Multispecific antibody
PH12014501628B1 (en) Stabilized formulations containing anti-ang2 antibodies
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
EA033399B1 (ru) Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2018004344A (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
WO2016164896A3 (en) Modulation of smn expression
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
BR112016002166B8 (pt) composição de biocida, e, método de controlar a proliferação de micróbios em um sistema usado na produção, transporte, armazenamento e separação de óleo bruto e gás natural
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
NZ728484A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
EA201691244A1 (ru) Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты
CL2017001685A1 (es) Método y composición para el secuestro del arsénico
NZ731103A (en) Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
MX2020012893A (es) Formulaciones de proteinas.
MX366208B (es) Transformación de la lenteja de agua y sus usos.
MX2019000177A (es) Formulaciones de anticuerpos.